Oncotarget

Research Papers:

Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney function

Sandro Gentile, Pamela Piscitelli, Francesca Viazzi, Giuseppina Russo, Antonio Ceriello, Carlo Giorda, Piero Guida, Paola Fioretto, Roberto Pontremoli, Felice Strollo and Salvatore De Cosmo and The AMD-Annals Study Group _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:62039-62048. https://doi.org/10.18632/oncotarget.18816

Metrics: HTML 1326 views  |   ?  


Abstract

Sandro Gentile1, Pamela Piscitelli2, Francesca Viazzi3, Giuseppina Russo4, Antonio Ceriello5,6, Carlo Giorda7, Piero Guida8, Paola Fioretto9, Roberto Pontremoli3, Felice Strollo10, Salvatore De Cosmo2 and The AMD-Annals Study Group11

1Department of Clinical and Experimental Medicine, University of Campania, Naples, Italy

2IRCSS Casa Sollievo della Sofferenza – Unit of Internal Medicine, Scientific Institute, San Giovanni Rotondo, Italy

3Università degli Studi, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

4Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

5Insititut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain

6U.O. Diabetologia e Malattie Metaboliche, Multimedica IRCCS, Milano, Italy

7Diabetes and Metabolism Unit, ASL Turin 5, Turin, Italy

8Statistical Consultant for Associazione Medici Diabetologi (AMD), Rome, Italy

9Department of Medicine, University of Padova, Padova, Italy

10Endocrinology and Metabolism, Elle-di, Rome, Italy

11Associazione Medici Diabetologi (AMD), Rome, Italy

Correspondence to:

Salvatore De Cosmo, email: sdecosm@tin.it

Sandro Gentile, email: s.gentile1949@gmail.com

Keywords: type 2 diabetes mellitus, nephropathy, age, antihyperglycemic treatment, eGFR

Received: May 03, 2017    Accepted: May 10, 2017    Published: June 28, 2017

ABSTRACT

We describe AHA utilization pattern according to age and renal function in type 2 diabetes mellitus (T2DM), in real-life conditions.

The analysis was performed using the data set of electronic medical records collected between 1 January and 31 December, 2011 in 207 Italian diabetes centers. The study population consisted of 157,595 individuals with T2DM. The AHA treatment regimens was evaluated. Kidney function was assessed by eGFR, estimated using the CKD-EPI formula. Other determinations: HbA1c, blood pressure (BP), low- density lipoprotein (LDL-c), total and high density lipoprotein cholesterol (TC and HDL-c), triglycerides (TG) and serum uric acid (SUA). Quality of care was assessed through Q score.

The proportion of subjects taking metformin declined progressively across age quartiles along with eGFR values, but remained high in oldest subjects (i.e. 54.5 %). On the other hand, the proportion of patients on secretagogues or insulin increased with aging (i.e. 54.7% and 37% in the fourth age quartile, respectively). The percentage of patients with low eGFR (i.e. <30 ml/min/1.73m2) taking either metformin or sulphonilureas/repaglinide was particularly high (i.e. 15.3% and 34.3% respectively).

In a large real-life cohort of T2DM, metformin or sulphonylureas/repaglinide, although not recommended, are frequently prescribed to elderly subjects with severe kidney disease.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18816